The prescription market for the antihypertensive drug losartan has shown an upward trend. Its market plummeted in 2021 following the detection of excess impurities in all losartan products but has since recovered obviously. Prescriptions of both single and combination losartan drugs have risen over 10% from three years ago. Analysts say the recurring impurity issues have diluted fears of impurities in drugs.

According to the drug research institution UBIST, outpatient prescriptions for losartan-containing drugs totaled KRW 70.3 billion in the third quarter, up 4.7% year-on-year. Compared to KRW 64.3 billion in the third quarter of 2022, prescriptions have increased 9.4% in two years.